Antigen News and Research

RSS

Yeast-based vaccine induces immune responses and reduces tumor size in mice

Scientists have found that vaccination with a heat-killed, non-toxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice.

1 Jul 2008

Seven elevated biomarkers predict prostate cancer risk with 86.6 percent reliability

A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.

26 Jun 2008

Jefferson scientists discover way to immunize mice against metastatic disease

Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have found a way to immunize mice against the development of metastatic disease.

24 Jun 2008

Discovery of an important factor in the development of B-cell lymphomas

Researchers at National Jewish Medical and Research Center have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer. The B-cell receptor on the surface of B cells can cooperate with the MYC oncogene to accelerate the development of lymphomas.

24 Jun 2008

Seven biomarkers that may help pinpoint prostate cancer recurrence found

A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.

24 Jun 2008

Patient's own infection-fighting T cells put late-stage melanoma into long-term remission

Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.

19 Jun 2008

Scientists cure advanced skin cancer with body's own cells

Scientists in the U.S. are claiming they have cured advanced skin cancer by using the patient's own cells.

19 Jun 2008

Seven biomarkers found that predict with 86 percent accuracy prostate cancer recurrence

A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, researchers at UT Southwestern Medical Center have found.

17 Jun 2008

Radiation therapy prolongs life in men with recurrent prostate cancer

Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. Surprisingly, survival benefits were best in men whose new tumors were growing fastest, according to results of a 'look-back' study of 635 men by Johns Hopkins Medical Institutions researchers reported June 18 in the Journal of the American Medical Association.

17 Jun 2008

Radioimmunotherapy targeting viral antigens shows potential to treat or prevent viral cancers

A new study, presented at the Society of Nuclear Medicine's 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.

16 Jun 2008

BN ImmunoTherapeutics starts clinical trials with prostate cancer vaccine

BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

4 Jun 2008

Bavarian Nordic enters trials with prostate cancer vaccine

Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

3 Jun 2008

IDM Pharma presents new data on IDM-2101 in non-small cell lung cancer

IDM Pharma, Inc. today announced follow-up results from the Phase 2 study of IDM-2101 showing that the product candidate was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in HLA-A2 positive patients with non-small cell lung cancer (NSCLC) who were treated with IDM-2101, compared to a parallel external control group of HLA-A2 negative non-treated patients.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

Novel chemo drug helps treat prostate cancer

Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.

1 Jun 2008

New research into superbug Clostridium difficile

New research into the toxins, virulence, spread and prevention of the superbug Clostridium difficile is reported in the June special issue of the Journal of Medical Microbiology. These findings will play a crucial role in providing us with ammunition in the fight against a sometimes deadly pathogen.

1 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

1 Jun 2008

New cancer vaccine protein target found

Cancer Research UK scientists have identified an important new protein target which could be used to produce highly focused vaccine therapies for cancer - according to research published in the Journal of Clinical Investigation.

25 May 2008

An alternative strategy for HIV vaccine research

Today, Advanced BioScience Laboratories, Inc. (ABL) and the University of Massachusetts Medical School (UMMS) report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.

22 May 2008

NIAID to advance B-cell approach to HIV vaccines

To advance underdeveloped approaches to designing a preventive HIV vaccine, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is launching a new program to foster the study of B cells, immune cells that can produce antibodies with the capacity to neutralize HIV.

20 May 2008